Brief: Sab Biotherapeutics On April 12, Completed Dosing Of Cohort 3 For Phase One Trials Of Sab-142
15/04/2024 23:12
April 15 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS: ON APRIL 12, COMPLETED DOSING OF
COHORT 3
FOR PHASE ONE TRIALS OF SAB-142, HAS NOT OBSERVED ANY INSTANCES
OF SERUM SICKNESSES
Further company coverage: SABS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies